14 research outputs found

    CHROMOBIOTICS: The Silent Neglect of a Salient Need

    Get PDF
    Colour has been one of the multi-faceted means of human development interwoven in the social structure and institutions which practically, psychologically and physiologically reveal the beauty and benefits of nature. This paper focuses on the subject of colour with particular emphasis on its often nuanced involvement in human well-being as regards health, and the vital edification of social life. It looks at the roles colour play in the life of humanity, dwelling on its functionalities. The study combines historical and discourse analysis methods based upon the qualitative research approach. How does colour draw on human inbuilt capacities to rejuvenate and restore the entire system to enliven and delight the senses? This inquiry is to incline human-kind to identify more with colour and be responsible and respectful in its application, to appreciate the intrinsic importance of the power of colour to life and to understand its contingent potential for maximum employment. The study provides exciting opportunity and inspiration to advance the reader’s knowledge and experience of colour in an overarching manner. Keywords: hue, chromatics, physio-psychological, colour sensibilities, holistic, chromo-therapy

    Subchronic toxicity studies of cocoa pod husk pectin intended as a pharmaceutical excipient in Sprague Dawley rats

    Get PDF
    Context: Excipients play a key role in the quality of medicines and contribute to viable delivery systems. This has intensified the search for new natural polymer pharmaceutical excipients. Cocoa pod husks (CPHs) are a rich source of pectin. A study of CPH pectin showed that it possesses the requisite physicochemical properties to be employed as a multi-functional pharmaceutical excipient. However, the safety of this natural polymer has not been evaluated. Aims: To conduct sub-chronic toxic effects of CPH pectin in Sprague Dawley rats to assess its safety as a pharmaceutical grade excipient. Methods: CPH pectin at doses of 0.714, 7.14, and 71.4 mg/kg were administered to male and female Sprague-Dawley rats by oral gavage over a 90-day period. Parameters assessed were food and water intake, urinalysis, serum biochemistry, wet organ weights, histopathology and pentobarbital-induced sleeping time. Results: CPH pectin at the orally administered doses had no significant effects on feed and water intake nor on biochemical parameters, except elevations in alkaline phosphatase at the medium and high dose in the female rat. There were also reductions in creatine kinase in both male and female rats at the medium dose after 60 days, suggesting a potential cardioprotective effect of CPH pectin. Conclusions: There were no adverse effects of CPH pectin on the kidneys, wet organ weights and histopathology of the rat tissues. Subchronic administration of cocoa pod husk pectin therefore, has no significant toxic effects

    Quality Assessment of Some Essential Children’s Medicines Sold in Licensed Outlets in Ashanti Region, Ghana

    No full text
    The quality of 68 samples of 15 different essential children’s medicines sold in licensed medicine outlets in the Ashanti Region, Ghana, was evaluated. Thirty-two (47.1%) of the medicines were imported, mainly from India (65.6%) and the United Kingdom (28.1%), while 36 (52.9%) were locally manufactured. The quality of the medicines was assessed using content of active pharmaceutical ingredient (API), pH, and microbial limit tests, and the results were compared with pharmacopoeial standards. Twenty-six (38.2%) of the samples studied passed the official content of API test while 42 (61.8%) failed. Forty-nine (72.1%) of the samples were compliant with official specifications for pH while 19 (27.9%) were noncompliant. Sixty-six (97.1%) samples passed the microbial load and content test while 2 (2.9%) failed. Eighteen (26.5%) samples passed all the three quality evaluation tests, while one (1.5%) sample (CFX1) failed all the tests. All the amoxicillin suspensions tested passed the three evaluation tests. All the ciprofloxacin, cotrimoxazole, flucloxacillin, artemether-lumefantrine, multivitamin, and folic acid samples failed the content of API test and are substandard. The overall API failure rate for imported products (59.4%) was comparable to locally manufactured (63.9%) samples. The results highlight the poor quality of the children’s medicines studied and underscore the need for regular pharmacovigilance and surveillance systems to fight this menace

    Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa

    Get PDF
    Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration. We formulated and evaluated the kinetic characteristics of the chitosan-pectin-based multiparticulate matrix of levodopa and carbidopa. Pectin was extracted from the cocoa husk, and the chitosan-pectin-based matrix was prepared by wet granulation. Formulations were evaluated for drug-excipient compatibility, drug content, precompression properties and in vitro release. For pharmacokinetic evaluation, rats were put into groups and administered either chitosan-pectin based matrix of levodopa/carbidopa, Sinemet® CR or levodopa/carbidopa immediate release powder. Rats were administered the different formulations of levodopa/carbidopa (20/5 mg/kg) per os every 12 hours. The pharmacokinetic parameters of levodopa were estimated for the various treatment groups. The percentage content of levodopa and carbidopa in the various formulations was within the acceptance criteria. The AUC0-24 for levodopa/carbidopa multiparticulate matrix (Formulation 3: 484.98 ± 18.70 μg.hr/mL); Formulation 4: 535.60 ± 33.04 μg.hr/mL), and Cmax (Formulation 3: 36.28 ± 1.52 μg/mL; Formulation 4: 34.80 ± 2.19 μg/mL) were higher than Sinemet® CR (AUC0-24 262.84 ± 16.73 μg.hr/mL and Cmax 30.62 ± 3.37 μg/mL). The t1/2 of the new formulation was longer compared to Sinemet® CR
    corecore